BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
US10316101B2 · kind B2 · utility
6Cited by
1References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 13, 2015 |
| Grant date | Jun 11, 2019 |
| Priority date | — |
| Expiry date | Apr 13, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a BCMA monoclonal antibody, conferring specific immunity against BCMA positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas, multiple myeloma and leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.